Treatment-refractory ulcerative colitis responsive to indigo naturalis
| Autor: | Julie P Saiki, Johan OL Andreasson, Kevin V Grimes, Lyn R Frumkin, Elvi Sanjines, Matthew G Davidson, KT Park, Berkeley Limketkai |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
clinical trials
Inflammatory Bowel Disease Gastroenterology Evaluation of treatments and therapeutic interventions Ulcerative Colitis Indigo Carmine Autoimmune Disease Indigofera Oral and gastrointestinal Colo-Rectal Cancer Mice Clinical Research 6.1 Pharmaceuticals Cytochrome P-450 CYP1A1 Quality of Life Animals Humans RNA Colitis Ulcerative Digestive Diseases ulcerative colitis Cancer |
| Zdroj: | BMJ open gastroenterology, vol 8, iss 1 BMJ Open Gastroenterology |
| Popis: | BackgroundIndigo naturalis (IN) is an herbal medicine that has been used for ulcerative colitis with an unclear mechanism of action. Indigo and indirubin, its main constituents, are ligands of the aryl hydrocarbon receptor (AhR). We assessed the safety, efficacy, and colon AhR activity of IN given orally to patients with treatment-refractory ulcerative colitis. The role of AhR in IN benefit was further evaluated with an AhR antagonist in a murine colitis model.MethodsThis open-label, dose-escalation study sequentially treated 11 patients with ulcerative colitis with either IN 500 mg/day or 1.5 g/day for 8 weeks, followed by a 4-week non-treatment period. The primary efficacy endpoint was clinical response at week 8, assessed by total Mayo score. Secondary endpoints included clinical remission, Ulcerative Colitis Endoscopic Index of Severity, quality of life, and colon AhR activity measured by cytochrome P450 1A1 (CYP1A1) RNA expression.ResultsTen of 11 (91%) patients, including 8/9 (89%) with moderate-to-severe disease, achieved a clinical response. Among these 10 patients, all had failed treatment with 5-aminosalicylic acid, 8 patients with a tumour necrosis factor (TNF)-alpha inhibitor, and 6 patients with TNF-alpha inhibitor and vedolizumab. Five patients were corticosteroid dependent. Clinical response was observed in all five patients who had been recommended for colectomy. Three patients achieved clinical remission. All patients experienced improved endoscopic severity and quality of life. Four weeks after treatment completion, six patients had worsened partial Mayo scores. Four patients progressed to colectomy after study completion. Colon CYP1A1 RNA expression increased 12 557-fold at week 8 among six patients evaluated. No patient discontinued IN due to an adverse event. Concomitant administration of 3-methoxy-4-nitroflavone, an AhR antagonist, in a murine colitis model abrogated the benefit of IN.ConclusionIN is a potentially effective therapy for patients with treatment-refractory ulcerative colitis. This benefit is likely through AhR activation.Trial registration numberNCT02442960. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|